Efficient Trial Design — FDA Approval of Valbenazine for Tardive Dyskinesia

In the case of valbenazine, which was recently approved for tardive dyskinesia, a small company pursued thoughtful, efficient trial design and an unusual application of remote assessment in clinical trials, and the FDA took an engaged and flexible approach to review.